Please assess the completion status of the following clinical trial:

Trial Title: The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* physician-diagnosed asthma~* age 6 or older~* pre-bronchodilator forced expiratory volume (FEV1) of at least 60% of predicted~* beta-agonist reversibility OR airways hyperreactivity by methacholine challenge~* Juniper Asthma Control Score of 1.5 or greater if not on daily controller~* good current health~Exclusion Criteria:~* current or past smoking (greater than 20 pack-years)~* chronic or current oral steroid therapy~* pregnancy, lack of effective contraception (when appropriate), lactation

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone (Type: ACTIVE_COMPARATOR): Participants continued fluticasone (100 microgram twice daily) treatment.
- Montelukast (Type: EXPERIMENTAL): Participants were changed to Montelukast (5 or 10 mg each night).
- Fluticasone plus salmeterol (Type: EXPERIMENTAL): Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.

Based on this trial design, predict the completion outcome and termination type (if applicable).